DOI QR코드

DOI QR Code

Initial titration with 200μg fentanyl buccal tablets: a retrospective safety analysis in Korean cancer patients

  • Kwon, Mi-Young (Department of Anesthesiology and Pain Medicine, National Medical Center) ;
  • Cho, Ha-Na (Department of Anesthesiology and Pain Medicine, National Medical Center) ;
  • Koo, Dong-Hoe (Division of Hematology and Oncology, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine) ;
  • Lee, Yun-Gyoo (Division of Hematology and Oncology, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine) ;
  • Oh, Sukjoong (Division of Hematology and Oncology, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine) ;
  • Lee, Seung-Sei (Division of Hematology and Oncology, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine)
  • Received : 2016.02.15
  • Accepted : 2016.09.28
  • Published : 2018.05.01

Abstract

Background/Aims: Managing breakthrough pain (BTP) is important for many cancer patients because of the rapid onset and unpredictable nature of the pain episodes. Fentanyl buccal tablets (FBTs) are a rapid-onset opioid indicated for BTP management. However, FBT titration is needed to optimize BTP management. In this study, we aimed to evaluate the safety and efficacy of initiating $200{\mu}g$ FBTs in Korean cancer patients. Methods: A retrospective analysis of medical records was performed on all advanced cancer patients treated with FBTs for BTP between October 2014 and July 2015. Patients who received initial doses of $200{\mu}g$ FBTs for at least 3 days and cases in which FBT was available at doses of 200, 400, and $800{\mu}g$ were included. Results: A total of 56 patients with a median age of 62 years (range, 32 to 80) were analyzed, 61% of whom were male. The median and mean values of morphine equivalent daily doses were 60 mg/day (range, 15 to 540) and $114.8{\pm}124.8mg/day$, respectively. The most frequent effective doses of FBT were $200{\mu}g$ (41 patients, 74%) and $400{\mu}g$ (12 patients, 21%). Three patients (5%) could not tolerate $200{\mu}g$ of FBT and discontinued treatment. Nausea, vomiting, somnolence, and dizziness were the most frequent treatment-related adverse events (AEs), and all AEs were grade 1 (mild) or 2 (moderate). Conclusions: FBT at the initial $200{\mu}g$ dosage was well-tolerated and effective as a BTP management strategy in Korean cancer patients. Further prospective studies are needed to determine appropriate initiating doses of FBT in Korean patients with opioid tolerance.

Keywords

Acknowledgement

Supported by : Samsung Biomedical Research Institute, Kangbuk Samsung Hospital

References

  1. McCarthy EP, Phillips RS, Zhong Z, Drews RE, Lynn J. Dying with cancer: patients' function, symptoms, and care preferences as death approaches. J Am Geriatr Soc 2000;48(5 Suppl):S110-S121. https://doi.org/10.1111/j.1532-5415.2000.tb03120.x
  2. Mercadante S. Breakthrough pain in cancer patients: prevalence, mechanisms and treatment options. Curr Opin Anaesthesiol 2015;28:559-564. https://doi.org/10.1097/ACO.0000000000000224
  3. Seo MS, Shim JY. Breakthrough cancer pain. Korean J Hosp Palliat Care 2015;18:1-8. https://doi.org/10.14475/kjhpc.2015.18.1.1
  4. Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence and characteristics. Pain 1990;41:273-281. https://doi.org/10.1016/0304-3959(90)90004-W
  5. Portenoy RK, Bruns D, Shoemaker B, Shoemaker SA. Breakthrough pain in community-dwelling patients with cancer pain and noncancer pain, part 2: impact on function, mood, and quality of life. J Opioid Manag 2010;6:109-116. https://doi.org/10.5055/jom.2010.0010
  6. Zeppetella G. Evidence-based treatment of cancer-related breakthrough pain with opioids. J Natl Compr Canc Netw 2013;11 Suppl 1:S37-S43. https://doi.org/10.6004/jnccn.2013.0213
  7. Jandhyala R, Fullarton JR, Bennett MI. Efficacy of rapid-onset oral fentanyl formulations vs. oral morphine for cancer-related breakthrough pain: a meta-analysis of comparative trials. J Pain Symptom Manage 2013;46:573-580. https://doi.org/10.1016/j.jpainsymman.2012.09.009
  8. Messina J, Darwish M, Fine PG. Fentanyl buccal tablet. Drugs Today (Barc) 2008;44:41-54. https://doi.org/10.1358/dot.2008.44.1.1178469
  9. Darwish M, Tempero K, Kirby M, Thompson J. Pharmacokinetics and dose proportionality of fentanyl effervescent buccal tablets in healthy volunteers. Clin Pharmacokinet 2005;44:1279-1286. https://doi.org/10.2165/00003088-200544120-00006
  10. Kleeberg UR, Filbet M, Zeppetella G. Fentanyl buccal tablet for breakthrough cancer pain: why titrate? Pain Pract 2011;11:185-190. https://doi.org/10.1111/j.1533-2500.2010.00414.x
  11. Fine PG, Narayana A, Passik SD. Treatment of breakthrough pain with fentanyl buccal tablet in opioid-tolerant patients with chronic pain: appropriate patient selection and management. Pain Med 2010;11:1024-1036. https://doi.org/10.1111/j.1526-4637.2010.00891.x
  12. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: adult cancer pain [Internet]. Washington (PA): National Comprehensive Cancer Network, c2017 [cited 2017 Jan 6]. Available from: http://www.nccn.org/professionals/physician_gls/pdf/pain.pdf.
  13. Portenoy RK, Taylor D, Messina J, Tremmel L. A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer. Clin J Pain 2006;22:805-811. https://doi.org/10.1097/01.ajp.0000210932.27945.4a
  14. Kang JH, Oh SY, Song SY, et al. The efficacy of low-dose transdermal fentanyl in opioid-naive cancer patients with moderate-to-severe pain. Korean J Intern Med 2015;30:88-95. https://doi.org/10.3904/kjim.2015.30.1.88
  15. Mercadante S, Ferrera P, Adile C, Casuccio A. Fentanyl buccal tablets for breakthrough pain in highly tolerant cancer patients: preliminary data on the proportionality between breakthrough pain dose and background dose. J Pain Symptom Manage 2011;42:464-469. https://doi.org/10.1016/j.jpainsymman.2010.12.010
  16. Mercadante S, Porzio G, Aielli F, Averna L, Ficorella C, Casuccio A. The use of fentanyl buccal tablets for breakthrough pain by using doses proportional to opioid basal regimen in a home care setting. Support Care Cancer 2013;21:2335-2339. https://doi.org/10.1007/s00520-013-1799-2
  17. Mercadante S, Gatti A, Porzio G, et al. Dosing fentanyl buccal tablet for breakthrough cancer pain: dose titration versus proportional doses. Curr Med Res Opin 2012;28:963-968. https://doi.org/10.1185/03007995.2012.683112
  18. Kleeberg UR, Davies A, Jarosz J, et al. Pan-European, open-label dose titration study of fentanyl buccal tablet in patients with breakthrough cancer pain. Eur J Pain 2015;19:528-537. https://doi.org/10.1002/ejp.577
  19. Chlebowski RT, Chen Z, Anderson GL, et al. Ethnicity and breast cancer: factors influencing differences in incidence and outcome. J Natl Cancer Inst 2005;97:439-448. https://doi.org/10.1093/jnci/dji064
  20. WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004;363:157-163. https://doi.org/10.1016/S0140-6736(03)15268-3
  21. Slatkin NE, Xie F, Messina J, Segal TJ. Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic pain. J Support Oncol 2007;5:327-334.
  22. Weinstein SM, Messina J, Xie F. Fentanyl buccal tablet for the treatment of breakthrough pain in opioid-tolerant patients with chronic cancer pain: a long-term, open-label safety study. Cancer 2009;115:2571-2579. https://doi.org/10.1002/cncr.24279
  23. Davies AN, Vriens J, Kennett A, McTaggart M. An observational study of oncology patients' utilization of breakthrough pain medication. J Pain Symptom Manage 2008;35:406-411. https://doi.org/10.1016/j.jpainsymman.2007.05.010
  24. Ashburn MA, Slevin KA, Messina J, Xie F. The efficacy and safety of fentanyl buccal tablet compared with immediate-release oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic pain. Anesth Analg 2011;112:693-702. https://doi.org/10.1213/ANE.0b013e318209d320
  25. Takigawa C, Goto F, Tanda S, et al. Breakthrough pain management using fentanyl buccal tablet (FBT) in combination with around-the-clock (ATC) opioids based on the efficacy and safety of FBT, and its relationship with ATC opioids: results from an open-label, multi-center study in Japanese cancer patients with detailed evaluation. Jpn J Clin Oncol 2015;45:67-74. https://doi.org/10.1093/jjco/hyu167
  26. Shin SH, Lee HS, Kim YS, et al. Clinical usefulness of hydromorphone-OROS in improving sleep disturbances in Korean cancer patients: a multicenter, prospective, open-label study. Cancer Res Treat 2014;46:331-338. https://doi.org/10.4143/crt.2013.130
  27. Shibutani K, Inchiosa MA Jr, Sawada K, Bairamian M. Pharmacokinetic mass of fentanyl for postoperative analgesia in lean and obese patients. Br J Anaesth 2005;95:377-383. https://doi.org/10.1093/bja/aei195
  28. Dahan A, Kest B, Waxman AR, Sarton E. Sex-specific responses to opiates: animal and human studies. Anesth Analg 2008;107:83-95. https://doi.org/10.1213/ane.0b013e31816a66a4
  29. Linnebur SA, O'Connell MB, Wessell AM, et al. Pharmacy practice, research, education, and advocacy for older adults. Pharmacotherapy 2005;25:1396-1430. https://doi.org/10.1592/phco.2005.25.10.1396
  30. Chau DL, Walker V, Pai L, Cho LM. Opiates and elderly: use and side effects. Clin Interv Aging 2008;3:273-278. https://doi.org/10.2147/CIA.S1847
  31. Martin TL, Woodall KL, McLellan BA. Fentanyl-related deaths in Ontario, Canada: toxicological findings and circumstances of death in 112 cases (2002-2004). J Anal Toxicol 2006;30:603-610. https://doi.org/10.1093/jat/30.8.603
  32. Baek SK, Kim do Y, Kang SY, Sym SJ, Kim YS, Lee JY. A Korean nationwide survey for breakthrough cancer pain in an inpatient setting. Cancer Res Treat 2016;48:768-774. https://doi.org/10.4143/crt.2015.087